DPP-4
16 drugs Metabolic
1
approved indications
16
Approved Drugs
6
Companies
2
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 16 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (2 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Boehringer Ingelheim 5 drugs
Merck 4 drugs
Takeda 2 drugs
By Therapeutic Area
Metabolic 14 drugs
Other 2 drugs
Drugs by Company PRO
Boehringer Ingelheim 5 drugs
Merck 4 drugs
Dr. Reddy's 2 drugs
AZURITY 1 drug
By Therapeutic Area
Metabolic 14 drugs
JENTADUETO, GLYXAMBI, LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN +10 more
Other 2 drugs
NESINA, TRADJENTA
Indications Treated
Type 2 diabetes mellitusType 2 Diabetes
All Drugs Targeting DPP-4
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| NESINA | Takeda | 2013 | 1 | |
| JENTADUETO | Boehringer Ingelheim | 2012 | 1 | Metabolic |
| GLYXAMBI | Boehringer Ingelheim | 2015 | 1 | Metabolic |
| LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | Dr. Reddy's | 2021 | 1 | Metabolic |
| LINAGLIPTIN | Dr. Reddy's | 2021 | 1 | Metabolic |
| JANUMET | Merck | 2007 | 1 | Metabolic |
| JANUMET XR | Merck | 2012 | 1 | Metabolic |
| TRIJARDY XR | Boehringer Ingelheim | 2020 | 1 | Metabolic |
| ZITUVIMET | ZYDUS LIFESCIENCES | 2023 | 1 | Metabolic |
| KAZANO | Takeda | 2013 | 1 | Metabolic |
| STEGLUJAN | Merck | 2017 | 1 | Metabolic |
| TRADJENTA | Boehringer Ingelheim | 2011 | 1 | |
| JENTADUETO XR | Boehringer Ingelheim | 2016 | 1 | Metabolic |
| JANUVIA | Merck | 2006 | 1 | Metabolic |
| ZITUVIO | ZYDUS LIFESCIENCES | 2023 | 1 | Metabolic |
| BRYNOVIN | AZURITY | 2025 | 1 | Metabolic |